Last checked at 19 Apr 2012 13:49
Tissue Regenix Group plc
Poster shown at Symposium for Advanced Wound Care (SAWC) in Atlanta, US.
YORK, 19th April, 2012 - Tissue Regenix, the regenerative medical device company, announces that the University Hospital of South Manchester (UHSM) is presenting a poster at SAWC with early data from the ongoing pilot clinical trial of decellularised human dermis being conducted with NHS Blood & Transplant (NHSBT). Full data from this trial is expected h2 2012.
ENDS
Enquiries regarding Tissue Regenix:
FTI Consulting |
|
Ben Atwell / John Dineen | +44 (0) 20 7831 3113 |
|
|
Peel Hunt LLP (Nominated Adviser) |
|
James Steel / Vijay Barathan | +44 (0) 20 7418 8900 |
About Tissue Regenix
Tissue Regenix, the RegenMed Company, was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.